30 Million Dollar Investment Cambrex Begins Construction of New R&D Facility in Italy

Source: Press release Cambrex 1 min Reading Time

Related Vendors

Cambrex has plans to invest 30 million dollars to develop its new research and development facility in Milan, Italy. With this project, the company aims to add advanced analytical development and process R&D capabilities.

Cambrex recently announced the start of construction on a new research and development facility at its Milan, Italy site. (Source:  Pixabay)
Cambrex recently announced the start of construction on a new research and development facility at its Milan, Italy site.
(Source: Pixabay)

New York/USA – Cambrex recently announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This 30-million-dollar investment will add advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants, reinforcing Cambrex’s commitment to supporting the pharmaceutical industry’s most complex small molecule development.

The Milan R&D expansion is expected to be completed in the second half of 2027. To accommodate future growth and rising demand for CDMO services, Cambrex has also acquired additional land adjacent to the site, ensuring the capacity to expand and innovate for years to come.

The Cambrex Profarmico Milano site, which marks its 80th anniversary this year, has a distinguished legacy of supporting pharmaceutical development and manufacturing for its global client base. The Milan team recently gathered to celebrate this milestone, reflecting on eight decades of scientific achievement and dedication to advancing human health.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

Claudio Russolo, Chief Operating Officer at Cambrex, commented: “Breaking ground on this new facility is a testament to the enduring legacy and expertise of our Milan team. For 80 years, this site has been a cornerstone of pharmaceutical manufacturing in Europe. With this expansion-n, we are investing not only in new technologies and capabilities, but in the future of our people and our partners.”

The investment builds on Cambrex’s legacy of scientific expertise and manufacturing excellence while positioning the company for its next chapter of growth. By expanding R&D capabilities in Milan, Cambrex is strengthening its ability to address the increasing complexity of today’s small molecule therapies.

(ID:50930926)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent